2/14
01:32 am
pmn
Promis Neurosciences (NASDAQ:PMN) was downgraded by analysts at
Wall Stre
Medium
Report
Promis Neurosciences (NASDAQ:PMN) was downgraded by analysts at
Wall Stre
2/6
10:34 am
pmn
Promis Neurosciences (NASDAQ:PMN) had its price target lowered by analysts at Guggenheim from $125.00 to $35.00. They now have a "buy" rating on the stock.
Low
Report
Promis Neurosciences (NASDAQ:PMN) had its price target lowered by analysts at Guggenheim from $125.00 to $35.00. They now have a "buy" rating on the stock.
2/4
05:28 pm
pmn
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 [Canadian Business Journal (Canada)]
High
Report
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 [Canadian Business Journal (Canada)]
2/4
04:05 pm
pmn
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
High
Report
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
1/30
08:00 am
pmn
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
High
Report
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
12/18
07:30 am
pmn
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
Medium
Report
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
12/10
07:30 am
pmn
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
Medium
Report
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk